Medunik Canada: A Team Strongly Committed to Bringing Novel Orphan Drugs to Canadians With Rare Diseases

A Strategic Turnkey Partnership Opportunity for International Pharmaceuticals

BLAINVILLE, Quebec, February 28, 2011 - Éric Gervais, Executive Vice-President of Medunik Canada (
medunikcanada.ca/en), is proud to announce the Management Team
(medunikcanada.ca/en/management) of this recently created company.
Medunik Canada is a Quebec pharmaceutical company with 60 employees and one
unique mission - bring novel orphan drugs to Canadians with rare diseases. To
this end, the Company is actively working at offering strategic partnerships
to international orphan drug companies that contemplate to introduce their
orphan drugs on the Canadian market.

Medunik Canada's Executive Vice-President said: "We are proud to have a
team whose commitment and excellence have allowed to build on our success.
Moreover, the Medunik Canada team has a proven record of commercializing
specialized small-market size products for underserved populations with
specific medical needs. Medunik Canada's team members are individually and
collectively committed to dedicate their experience and expertise to bringing
currently unavailable orphan drugs to Canadian with rare diseases."

Medunik Canada's Executive Vice-President, explained the company's
business approach: "Through in-licensing partnerships, Medunik Canada is
bridging the gap by providing turn-key operations - ranging from regulatory
approval strategy to post-approval activities - to assure the commercial
success of the partners' novel orphan treatments. Our long-standing success
in specialty markets, coupled with our solid and independent financial
backing, our infrastructure and our team's dedication to medically unique
populations makes Medunik Canada a strategic fit for our partners with a
global orphan drug strategy."

Medunik Canada's team benefits from the collaboration of an Advisory
Committee (www.medunikcanada.com/en/advisory-board) composed of Abbey
S. Meyers, founder and Past President of the US National Organization for
Rare Disorders (NORD), Marlene E. Haffner, M.D., M.P.H., former FDA's
Director of Orphan Product Development and Jean F. Campbell, Former
Vice-President, Membership Development at NORD.

Medunik Canada's Executive Vice-President Éric Gervais was recently
featured in the thirty-ninth edition of the Zillion Business Review. The
Zillion Business Review is written for and about internationally oriented
businesses.

Biographical notes of Medunik Canada's team members

Éric Gervais (medunikcanada.ca/files/Eric_Gervais_Bio-en.pdf)

Raymond Hébert (medunikcanada.ca/files/Raymond-Hebert_en.pdf)

Jean-Luc St-Onge (medunikcanada.ca/files/Jean-Luc-St-Onge_en.pdf)

Matthieu Lacroix (medunikcanada.ca/files/Matthieu-Lacroix_en.pdf)

Carole Boyer (medunikcanada.ca/files/Carole-Boyer_en.pdf)

Michael Gallo (medunikcanada.ca/files/Michael-Gallo_en.pdf)

Christine Walter (medunikcanada.ca/files/Christine-Walter_en.pdf)

About Medunik Canada

Medunik Canada was created in early 2010 with the mission to bring novel
orphan treatments to Canadian people with rare diseases. Medunik Canada is a
natural complement to its sister company Duchesnay Inc. (
duchesnay.com/), a specialty pharmaceutical company providing safe and
effective treatment options to pregnant women, who represent a small-size
population with special health needs. Both Medunik Canada and Duchesnay are
part of Le Groupe Pharmaceutique Boivin, a Canadian family-owned organization
based in the greater Montreal area since 1955.

For further information:

Media Relations: Christine Walter +1-450-433-4441
cwalter@medunikcanada.com Business Development: Raymond Hebert
+1-450-433-4441 rhebert@medunikcanada.com Web site:
www.medunikcanada.com

Media Relations: Christine Walter +1-450-433-4441, cwalter at medunikcanada.com Business Development: Raymond Hebert, +1-450-433-4441 rhebert at medunikcanada.com